📢 Just published 💃 in @JCOGO_ASCO: the @APODDC Working Group’s recommendations on using real-world evidence (RWE) to advance oncology drug development across Asia-Pacific. Why this matters for APAC: 🌏 Pivotal trials often don’t reflect our patients. #Ethnicity, #tumourbiology, #comorbidities, #access and treatment patterns vary hugely across the region. 📋 Only 🇨🇳 China, 🇯🇵 Japan and 🇹🇼 Taiwan currently have formal RWE regulatory guidance. ⏳ In many #APAC systems, reimbursement lags regulatory approval by years. That window is an opportunity for local #RWD to show whether trial benefits hold up in our own health systems. 💊 RWE can support #label_extensions, #external_controls for #rare and #biomarker_defined cancers, #postmarketing safety and HTA, as a complement to RCTs. Key recommendations: ✅ Harmonised data standards and quality assurance ✅ Risk-proportionate governance, with federated analyses where data can’t cross borders ✅ Sustainable funding for registries and the people who run them ✅ A tiered infrastructure model so resource-limited centres can start small ✅ Transparent public–private partnerships and capacity building A truly international effort 🌐 with the entire @apoddc team including co-authors @pankajpanda86 @DrBenTran @ToshioShim1025 #PJVoon @fredtingmd #TakafumiKoyama #DaphneDay #KArnoldChan @wonglaihung and @danieltanmd Open access 👇 doi.org/10.1200/GO-26-00217 #RWE #RealWorldEvidence #DrugDevelopment #AsiaPacific #Oncology @APCLC_2023 @CUHKMedicine #globaloncology

Well done #PDG4 at @MOGA_ORG @myESMO #ACORD26 workshop! Congrats on successfully putting your clinical research protocol together. Looking forward to seeing your projects come to fruition 😁 #drugdevelopment @AACR @ASCO